# ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

> **NCT06997081** · PHASE2 · RECRUITING · sponsor: **University of Miami** · enrollment: 104 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Elranatamab

## Key facts

- **NCT ID:** NCT06997081
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-16
- **Primary completion:** 2030-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06997081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06997081, "ERd Combination Treatment in Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT06997081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*